← NovaBridge Biosciences NBP
Market Price
$1.96
Market Cap
$220.89M
P/E Ratio
N/A
Revenue (FY 2025)
↑1.7% YoY
$7.61M
Full year reported
Net Income
↓-108.1% YoY
-$46.27M
Net Margin: -607.9%
Free Cash Flow
↑32.6% YoY
$1.00M
FCF Yield: 0.45%
EPS (Diluted)
↓-75.0% YoY
$-0.21
Basic: $-0.21
Return on Equity
Efficiency
-20.0%
ROA: -17.8%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (NBP)
All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
- FY 2018: Revenue YoY (+6168.2%) is identical to Gross Profit YoY (+6168.2%). Verify the underlying Revenue and Gross Profit values for FY 2018 and FY 2017.
- FY 2019: Revenue YoY (-92.0%) is identical to Gross Profit YoY (-92.0%). Verify the underlying Revenue and Gross Profit values for FY 2019 and FY 2018.
- FY 2020: Revenue YoY (+5386.7%) is identical to Gross Profit YoY (+5386.7%). Verify the underlying Revenue and Gross Profit values for FY 2020 and FY 2019.
- FY 2024: Revenue YoY (+92.3%) is identical to Gross Profit YoY (+92.3%). Verify the underlying Revenue and Gross Profit values for FY 2024 and FY 2023.
- FY 2025: Revenue YoY (+1.7%) is identical to Gross Profit YoY (+1.7%). Verify the underlying Revenue and Gross Profit values for FY 2025 and FY 2024.
| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2010 | — | — | — | — | — | — | — | — | — | — |
| FY 2011 | — | — | — | — | — | — | — | $2.6M | $1.9M | — |
| FY 2016 | — | — | — | — | — | — | — | — | — | — |
| FY 2017 | $0.9M | — | $0.4M | — | — | $-51.93 | — | $-252.2M | $-254.5M | — |
| FY 2018 | $53.8M | +6,168.2% | $25.4M | $-402.8M | — | $-61.70 | -18.8% | $-280.7M | $-295.1M | -16.0% |
| FY 2019 | $4.3M | -92.0% | $2.0M | $-208.6M | +48.2% | $-28.90 | +53.2% | $-124.7M | $-126.4M | +57.2% |
| FY 2020 | $236.4M | +5,386.7% | $111.7M | $72.2M | +134.6% | $0.46 | +101.6% | $66.4M | $65.2M | +151.6% |
| FY 2021 | $13.8M | -94.2% | $6.5M | $-365.9M | -607.0% | $-2.09 | -554.3% | $-152.7M | $-157.4M | -341.3% |
| FY 2022 | $-32.1M | -332.6% | $-36.1M | $-363.5M | +0.6% | $-1.92 | +8.1% | $-159.9M | $-166.5M | -5.8% |
| FY 2023 | $3.9M | +112.1% | $1.8M | $-206.4M | +43.2% | $-1.08 | +43.7% | $-183.8M | $-185.4M | -11.3% |
| FY 2024 | $7.5M | +92.3% | $3.5M | $-22.2M | +89.2% | $-0.12 | +88.9% | $0.8M | $0.8M | +100.4% |
| FY 2025 | $7.6M | +1.7% | $3.6M | $-46.3M | -108.1% | $-0.21 | -75.0% | $1.0M | $1.0M | +32.6% |
Valuation
Market Price
$1.96
Market Cap
$220.89M
Enterprise Value
$15.50M
P/E Ratio
N/A
P/B Ratio
0.98
FCF Yield
0.45%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
47.25%
Operating Margin
-1,238.59%
Net Margin
-607.92%
Return on Equity (ROE)
-20.03%
Return on Assets (ROA)
-17.76%
Asset Turnover
0.03x
Revenue 3-Yr CAGR
N/A
Financial Health & Liquidity
Current Ratio
7.49
Cash Ratio
236.40
Debt / Equity
0.023
Debt / Assets
0.020
Cash & Equivalents
$210.63M
Total Debt
$5.24M
Book Value / Share
$2.00
Cash Flow Efficiency
Operating Cash Flow
$1.01M
Capital Expenditures (CapEx)
$7.00K
Free Cash Flow
$1.00M
OCF / Revenue
13.28%
FCF / Revenue
13.19%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
$-0.21
EPS (Basic)
$-0.21
Dividends / Share
N/A
Book Value / Share
$2.00
EPS YoY Growth
-75.00%
Balance Sheet (FY 2025)
Total Assets
$260.52M
Total Liabilities
$29.58M
Stockholders' Equity
$230.94M
Current Assets
$6.68M
Current Liabilities
$891.00K